Clinical trials: Autoimmune Hair Loss

Alopecia Areata

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

• Completed
• Age: 18 to 70 years
• Phase 2
• Results posted

The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams [mg] and 3 mg) in participants with moderate-to-severe alopecia areata (AA).

Trial name

NCT04556734

Testing

Etrasimod

Where

42 sites in United States, Canada

Volunteers

80 people

Sponsor

Pfizer